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Abstract
Background. The effect of cinacalcet on the structural
pattern of hyperplastic parathyroid glands was evaluated,
using high-resolution colour Doppler (CD) sonography,
in haemodialysis patients with severe, inadequately con-
trolled, secondary hyperparathyroidism (sHPT).
Methods. Nine patients (6 males, 3 females; mean age
± SD, 55.5 ± 12.6 years) received cinacalcet, with adap-
tation of existing concomitant therapies. Biochemical pa-
rameters and themorphology and vascular pattern of hyper-
plastic parathyroid glands were measured at baseline and
every 6 months thereafter, for a follow-up period of 24–30
months.
Results. At baseline, 28 hyperplastic glands were iden-
tified. Cinacalcet led to a reduction in glandular volume
during the course of the study: 68% in glands with a base-
line volume <500 mm3 and 54% in glands with a baseline
volume ≥500 mm3. The mean volume ± SD of glands
<500 mm3 changed significantly from the baseline (233 ±
115 mm3) to the end of follow-up (102 ± 132 mm3, P =
0.007). Levels of mean serum phosphorus, calcium and
calcium–phosphorus product decreased, but not signifi-
cantly, whereas there were significant decreases in mean
parathyroid hormone ± SD levels (1196 ± 381 pg/ml ver-
sus 256± 160 pg/ml;P< 0.0001) and alkaline phosphatase
± SD levels (428 ± 294 versus 223 ± 88 IU/l; P = 0.04),
accompanied by an improvement in a subjective clinical
score.
Conclusions.Cinacalcet, in combinationwith conventional
treatments, led to an improvement in biochemical and clin-
ical parameters of sHPT and reduced glandular volume in
patients with severe sHPT. Volume reduction was more ev-
ident in smaller glands. Longer term, larger, randomized
clinical trials are needed to confirm these preliminary find-
ings and to further define a more systematic approach in
the treatment of sHPT.
Correspondence and offprint requests to: Mario Meola, Nephrology and
Dialysis Unit, Department of InternalMedicine, University of Pise, Hospi-
tal of Cisanello, Via Paradisa, 2 - 56127 Pise, Italy. Tel: +39-050-997260;
Fax: +39-050-997285; E-mail: mmeola@int.med.unipi.it
Keywords: chronic kidney disease; cinacalcet;
high-resolution sonography; parathyroid hyperplasia;
secondary hyperparathyroidism
Introduction
Secondary hyperparathyroidism (sHPT) develops progres-
sively during the course of chronic kidney disease (CKD).
Phosphorus retention and reduced synthesis of 1–25 vita-
min D result in low serum calcium levels, which causes a
feedback secretion of intact parathyroid hormone (iPTH).
Long-term hyperstimulation of parathyroids enhances cell
proliferation resulting first in diffuse polyclonal hyperpla-
sia and finally in monoclonal nodular hyperplasia [1–3].
Since nodular hyperplasia does not involve all parathyroid
glands, or all patients with CKD, to the same degree, it is
logical to suppose that genetic mechanisms are involved
[4–7].
Glandular volume is a key marker for the severity of
sHPT and increased secretion of iPTH [3,8]. However, only
indirect measurements of parathyroid volumes are possible
due to their location, small size and the difficulty in ob-
taining accurate measurements of glandular volume with
common non-invasive techniques. In healthy patients, the
identification of parathyroid glands is particularly difficult
[9]. In sHPT, hyperplastic glands become distinguishable
from the thyroid parenchyma due to their increased cellu-
larity. High-resolution colour Doppler (CD) sonography is
the only tomographic technique able to measure accurately
volumetric variations in parathyroid glands. There is no
defined size limit over which a parathyroid gland can be
considered pathological, although a hypoechoic gland with
two diameters >5 mm is generally considered to be hyper-
plastic [10]. In addition, CD sonography simultaneously
provides semi-quantitative measurements of glandular per-
fusion [11–13].
Patients are considered to have severe sHPT when serum
phosphorus (P), calcium (Ca), the Ca–P product (Ca × P)
and iPTH levels can no longer be adequately controlled by
conventional therapies [14], and when clinical symptoms
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are associated with a significantly increased risk of car-
diovascular morbidity and mortality [14,15]. Following in-
ternational guidelines, parathyroidectomy (PTX) becomes
mandatory when one or more parathyroid glands are en-
larged (volume >500 mm3), iPTH values are >700 pg/ml
and the response to conventional therapy is poor [13,16–
19].
The introduction of the calcimimetic cinacalcet
(Mimpara R©/Sensipar R©) into clinical practice has led to its
use in patients with various degrees of severity of sHPT, in-
cluding those who are not candidates for PTX. Cinacalcet
is an allosteric modulator of the calcium receptor (CaR).
It increases the sensitivity of the CaR to activation by ex-
tracellular calcium and thus suppresses PTH release, while
simultaneously lowering levels of serumP andCa, andCa×
P [13,20–23]. However, no studies to date have been pub-
lished evaluating morphological variations in the parathy-
roid glands of maintenance haemodialysis (MHD) patients
treated with cinacalcet.
The aim of this studywas to evaluate the effect of cinacal-
cet on the morphology (volume, structure and vascular pat-
tern) of parathyroid glands in MHD patients with severe
sHPT, in relation to biochemical parameters and the dura-
tion of therapy, using high-resolution CD sonography.
Subjects and methods
Patients
Nine consecutive MHD patients awaiting PTX at our
nephrology and dialysis unit (6 males, 3 females; mean
age ± SD, 56 ± 13 years) were recruited and prospectively
studied. All patients had severe sHPT, and none, due to age,
or cardiovascular or general conditions, was an ideal candi-
date for PTX. In our centre, patients undergo subtotal PTX
when one or more glands have a volume>500 mm3 by CD
sonography and iPTH values are >700 pg/ml, to avoid the
risk of nodular degeneration of the remnant glands. During
the period of the study, one additional young patient await-
ing transplantation stopped treatment with cinacalcet after
1 month due to drug intolerance (epigastralgia). She was
excluded from the study and underwent PTX.
As comparison, we have considered a historical control
group that included 11 consecutive patients with clinical,
biochemical and morphological signs of severe and refrac-
tory sHPT treated with conventional PTX between 2003
and 2006.
Study design
The treatment protocol integrated cinacalcet with patients’
existing pharmacological sHPT therapies (calcium supple-
ments, phosphate binders or vitamin D sterols). Treatment
with cinacalcet did not require a pharmacological wash-out
period. The starting dose of cinacalcet was 30 mg/day. This
was increased by 30 mg every 21–30 days, until the pa-
tient reached the targets indicated in the KDOQITM guide-
lines. The maximum dose of cinacalcet administered was
150 mg/day. As cinacalcet treatment was used for compas-
sionate use before commercialization in Italy, all patients
signed an informed consent form.
Conventional therapy was adjusted during follow-up ac-
cording to theOPTIMAalgorithm [23].When indicated, the
dose of a vitamin D sterol was reduced by∼50% in sequen-
tial steps until a minimum administered dose was reached:
intravenous calcitriol, 0.5 µg three times per week; intra-
venous alfacalcidol, 1µg three times per week; intravenous
paricalcitol, 2 µg three times per week; oral calcitriol, 0.25
µg three times per week; oral alfacalcidol, 0.25 µg/day.
The dose of cinacalcet was reduced if a patient was not
receiving vitamin D. Phosphate binder dosages were mod-
ulated depending on serum Ca and P levels in an attempt to
maintain Ca × P within the international guidelines range
[23,13].
Biochemical parameters [P, Ca, Ca × P, iPTH and alka-
line phosphatase (ALP)] and the morphology and vascular
pattern of the parathyroid glands were measured at baseline
and every 6 months thereafter, for a follow-up period of
24–30 months. Changes in cinacalcet dosing and the onset
of any side effects were recorded throughout this period.
iPTH was measured using the Nichols IRMA method.
To prove the effect of cinacalcet on the functional be-
haviour of parathyroid glands, an additional experimentwas
performed to see whether or not serum iPTH increased im-
mediately after an interruption of cinacalcet. In the absence
of any change in other treatments, the drug was stopped for
2 weeks in three patients who had experienced the highest
reductions in iPTH and gland volume and in two patients
who had experienced the highest reduction in iPTH, but
only mild reductions in gland volume and vascularization.
iPTH was measured twice, under exactly the same condi-
tions (i.e. at morning, before the dialysis, at the start and at
the end of the test and finally 2 weeks after restarting the
therapy).
Imaging techniques
High-resolution CD sonography was carried out in our
unit by an expert nephrologist using digital equipment
(Logiq 9TM, General Electric Medical Systems, USA) and
a small parts linear array (matrix 1.5D). Transmission fre-
quency (9–14 MHz) provided an axial and a lateral reso-
lution of 0.2 mm. Images were acquired using harmonic
imaging and spatial compounding to reduce speckle.
Patients were examined with the neck hyperextended in
a supine decubitus. The anatomical location of the parathy-
roid glands [23–25] was determined by a sequence of trans-
verse, longitudinal and oblique scans in the laterocervical
region from the corner of the jaw to the superior medi-
astinum. Themediocervical transverse scanwas essential to
identify the thyroid lobes and isthmus. The same transverse
scan along the laterocervical line was used to identify the
usual landmarks (sternocleidomastoid muscle, pre-thyroid
muscles, epiaortic vessels, oesophagus, pre-vertebral mus-
cles). Longitudinal and oblique scans were used to define
the anatomical relationships with the homolateral thyroid
lobe, the oesophagus, the long muscles of the neck, the lat-
erocervical vessels and the thyroid and cricoid cartilages.
Additional oblique scans were carried out on the jugular
fossa to identify the inferior parathyroid glands, sometimes
located in the superior mediastinum or in the horn of the
thymus. The inferior thyroid artery in the mid-cervical tract
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Fig. 1. Longitudinal scan of right lobe of thyroid. The image shows a
hypervascularized parathyroid gland, characterized by an enlarged feeding
artery at the hilum, a peripheral arc of vascularity and ray-like endonodular
vessels.
was also located to define vascularization of parathyroid
glands.
Normal parathyroid glands are rich in adipose cells so
they are indistinguishable from the thyroid parenchyma
even using high-resolution probes. Glandular hyperplasia
changes the ultrasound pattern: the gland becomes diffusely
hypoechoic and is outlined from the thyroid parenchyma
by a thin hyperechoic edge. Using the ellipsoid formula
(4/3 π × 1/2 anteroposterior diameter × 1/2 latero-lateral
diameter × 1/2 craniocaudal diameter), it is possible to
calculate the gland volume in mm3. Glands with nodular
hyperplasia appear as hypoechoic nodules that are well out-
lined from the thyroid lobes in common locations. Glands
with at least two diameters>5mmand a volume<500mm3
are considered definitively to be pathological (diffuse or
polyclonal hyperplasia), whereas glands with a diameter
>1 cm and overall volume ≥500 mm3 are considered to
have monoclonal nodular degeneration [16,17,25,26]. Pa-
rameters used to evaluate morphological changes in the
glands were (1) gland diameter and volume; (2) presence
of anechoic areas (suggesting cystic degeneration) [27] and
absence of vascularized areas; (3) echogenicity.
B-Mode sonography was combined with CD sampling.
Nodular flow was characterized using a pulse repetition
frequency (PRF) <800 kHz, CD frequency 3.8 MHz and
mid-high colour gain (set to 45–50, with a range of 0–60),
and a steering angle of 30◦. Vascular pattern is a semi-
quantitative parameter, dependent on both the settings of the
sonolayer and subjective evaluation by the operator. Three
different vascularization patterns were identified: type 1,
glands with no Doppler signal; type 2, hypovascularized
glands with a poor or weak Doppler signal, represented
by occasional colour spots in the hilar/endonodular region;
type 3, hypervascularized glands having an enlarged feed-
ing artery at the hilum, a peripheral arc of vascularity and/or
ray-like endonodular vessels [27–29] (Figure 1). All sono-
graphic examinations were recorded and reviewed by two
other skilled operators who used the same parameters. An
intra-class correlation coefficient (ICC) was used to as-
sess inter-observer reliability. Intra-observer ICC was 0.95
whereas inter-observer ICC was 0.91 for measurements of
glandular volume.
Statistical analysis
Data were analysed using Student’s t-test for paired and
non-paired data and were considered significant for values
of P < 0.05. The conformity of our data set was measured
using the ICC (an ICC >0.70 was considered valid). The
correlation between two variables was assessed using the
Pearson product–moment correlation coefficient.
Results
Baseline clinical and biochemical parameters
Causes of CKD were hereditary and/or congenital (n =
4), glomerulonephritis (n = 3), pyelonephritis (n = 1) and
chronic ischaemic nephropathy (n = 1). Causes of CKD
in the control group were hereditary and/or congenital
(n = 3), glomerulonephritis (n = 6) and pyelonephritis
(n = 2). Baseline biochemical parameters of mineral
metabolism were consistent with severe sHPT and were
similar in the two groups. Mean values of serum P and Ca,
Ca × P, iPTH, ALP, mean dialytic age and mean duration
of pre-dialysis CKD duration are presented in Table 1.
Baseline morphological parameters
High-resolution sonography identified two or more hyper-
plastic parathyroid glands in each patient (two glands in
two patients, three glands in four patients and four glands
in three patients), giving a total of 28 hyperplastic glands.
Twenty-five glands were in common locations, and three
Table 1. Baseline clinical, biochemical and sonographic parameters
Historical
control group
(n = 11)
Cinacalcet
group (n = 9)
P-value
Mean age ± SD (years) 46 ± 14 56 ± 13 NS
Sex 5 M/6 F 6 M/3 F
Mean ± SD duration of
dialysis uraemia
(months)
62 ± 48 111 ± 75 NS
Mean ± SD duration of
pre-dialysis uraemia
(months)
74 ± 53 136 ± 67 0.01
Phosphorus ± SD (mg/dl) 6.3 ± 0.8 5.4 ± 1.3 NS
Calcium ± SD (mg/dl) 10.1 ± 0.7 9.5 ± 0.7 0.03
Ca × P ± SD (mg2/dl2) 64 ± 11 50 ± 11 0.01
iPTH ± SD (pg/ml) 1405 ± 590 1196 ± 381 NS
ALP ± SD (IU/l) 265 ± 113 428 ± 294 NS
Parathyroid glands (n) 36 28
<500 mm3 19 15
≥500 mm3 17 13
Mean ± SD glandular
volume (mm3)
798 ± 740 731 ± 897 NS
B-mode structural pattern Hypoechoic Hypoechoic
Vascular pattern, n (%)
Type 1 0 0
Type 2 7 (19) 3 (11)
Type 3 29 (81) 25 (89)
Involutive cystic areas 0 0
ALP, alkaline phosphatase; Ca × P, calcium–phosphorus product; iPTH,
intact parathyroid hormone; NS, not significant.
iPTH: 1 pmol/l = 1 pg/ml × 0.105; calcium: 1 mmol/l = 1 mg/dl × 0.25;
phosphorus: 1 mmol/l = 1 mg/dl × 0.323.
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Table 2. Pharmacological treatment at baseline
Historical
control group
(n = 11)
Cinacalcet
group (n = 9)
Vitamin D
Received vitamin D derivative,
n (%)
9 (81) 8 (89)
Mean ± SD paricalcitol dose
equivalentsa (µg/week)
3.2 ± 1.2 3.6 ± 1.9
Phosphate binders
Sevelamer
Received sevelamer, n (%) 8 (72) 5 (56)
Mean ± SD sevelamer dose
(mg/day)
4220 ± 580 3360 ± 876
Calcium-based phosphate
binder
Received calcium-based
phosphate binder, n (%)
6 (54) 3 (33)
Mean ± SD total elemental
calcium intake (mg/day)
3600 ± 980 3100 ± 1087
a2 µg paricalcitol = 1 µg doxercalciferol = 0.5 µg calcitriol.
were in the jugular fossa. None of the glands showed signs
of cystic degeneration. The mean volume ± SD was 731 ±
897 mm3 (range 42–4180 mm3): 15 glands had a volume
<500 mm3, whereas 13 glands had a volume ≥500 mm3;
CD sampling revealed a hypervascular pattern in the hy-
perplastic glands. Pre-surgical sonography in the historical
control group revealed 36 glands (two glands in two pa-
tients, three glands in four patients and four glands in five
patients). The mean volume ± SD was 798 ± 740 mm3
(range 55–2257 mm3): 19 glands had a volume<500 mm3
and 17 glands a volume ≥500 mm3. None of the glands
showed cystic degeneration. Also in this group, CD sam-
pling revealed a hypervascular pattern in the hyperplastic
glands. The clinical, biochemical and sonographic profiles
of the two groups are outlined in Table 1. Forty glands were
excised. At histological examination, 18 glands showed a
nodular pattern, while 22 glands revealed a diffused hyper-
plasia. Glands with a nodular pattern showed a sonographic
volume ≥500 mm3 in 84% of cases.
Baseline pharmacological sHPT therapies and clinical
scores
Table 2 shows baseline pharmacological sHPT therapies.
The historical control group received similar conventional
therapies [vitaminDderivatives or phosphate binders (seve-
lamer or calcium-based phosphate binders) at various doses
and in various combinations] to the cinacalcet group. In the
study group, the severity of sHPT-related clinical symptoms
(diffuse bone pain, articular tenderness, walking difficul-
ties, muscular pain and itching) was subjectively evaluated
and scored by two clinicians, from 0 to 4: 0= no symptoms;
1 = mild osteoarticular tenderness, with no adverse effect
on daily life; 2 = diffuse osteoarticular tenderness, limit-
ing normal activities; 3= diffuse osteoarticular tenderness,
with total limitation of daily activities and/or itching on ad-
ministration of drugs; 4= unbearable itching accompanied
by skin injury due to scratching, severe deficiency in limb
Fig. 2. (A–C). (A) Variations in mean serum phosphorus (P) and calcium
(Ca), (B) the Ca–P product (Ca × P), and (C) intact parathyroid hormone
(iPTH) and alkaline phosphatase (ALP) following treatment with cinacal-
cet. The mean serum P and Ca, and Ca × P did not change significantly
with cinacalcet treatment. Mean ± SD iPTH decreased from 1196 ± 381
pg/ml at baseline to 256± 160 pg/ml at the end of follow-up (P< 0.0001).
Mean± SD serum ALP decreased from 428± 294 IU/l at baseline to 223
± 88 IU/l at the end of follow-up (P = 0.04).
functionality, and limited ability to walk. Clinical scores
were similar between the two groups.
Follow-up periods and dose adjustments
Four patients remained in the study for a 30-month follow-
up period. Five patients had a follow-up of 24 months, two
of whom died due to major cardiovascular events. Three
patients received a final cinacalcet dose of 30 mg/day, four
patients received 60 mg/day and two patients received 120
mg/day.
Effect of cinacalcet on biochemical parameters
Mean serum P and Ca, and Ca × P decreased throughout
the course of the study, but not significantly. However, there
was a significant change in mean levels of iPTH ± SD
(1196 ± 381 pg/ml versus 256 ± 160 pg/ml; P < 0.0001)
and mean serum ALP ± SD values (428 ± 294 versus 223
± 88 IU/l; P = 0.04). Variations in mean serum P and Ca,
Ca × P, iPTH and ALP are shown in Figure 2. Values for
biochemical parameters at baseline and at the end of the
follow-up period are shown in Table 3.
Effect of cinacalcet on clinical scores
Clinical scores, measuring subjective symptoms, showed
substantial improvement during the course of the study in all
patients. In patients with severe symptomatology (baseline
score of 4), the score improved by two or three points,
with an improvement in pain, osteoarticular tenderness and
itching.
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Table 3. Biochemical parameters at baseline and following treatment with
cinacalcet
Baseline End of follow-up
(24–30 months)
P-value
Phosphorus ± SD (mg/dl) 5.4 ± 1.3 4.5 ± 0.8 NS
Calcium ± SD (mg/dl) 9.5 ± 0.7 9.3 ± 0.4 NS
Ca × P ± SD (mg2/dl2) 50 ± 11 42 ± 8 NS
iPTH ± SD (pg/ml) 1196 ± 381 256 ± 160 <0.0001
ALP ± SD (IU/l) 428 ± 294 223 ± 88 0.04
ALP, alkaline phosphatase; Ca × P, calcium–phosphorus product; iPTH,
intact parathyroid hormone; NS, not significant.
iPTH: 1 pmol/l = 1 pg/ml × 0.105; calcium: 1 mmol/l = 1 mg/dl × 0.25;
phosphorus: 1 mmol/l = 1 mg/dl × 0.323.
Table 4. Sonographic variations of parathyroid glands after cinacalcet
treatment
Baseline End of follow-up P-value
Glands (N) 28 23a
<500 mm3 15 17a
≥500 mm3 13 6
Total mean ± SD
volume (mm3)
731 ± 897 539 ± 1017 NS
<500 mm3 233 ± 115 102 ± 132b 0.007
≥500 mm3 1036 ± 1062 837 ± 1290b NS
Reduction in volume
(%)
60
<500 mm3 68
≥500 mm3 54
Cystic areas (N) 0 13
<500 mm3 5
≥500 mm3 8
NS, not significant.
aFive glands with baseline volume <500 mm3 became indistinguishable.
bOne gland in each group increased in volume due to involutive cystic
degeneration.
Effect of cinacalcet on morphological ultrasound
parameters
Twenty-eight glands of various shapes and volumes were
examined at baseline and at 6 monthly intervals until the
end of the follow-up period. Overall, the mean volume ±
SD of the glands did not change significantly during the
course of the study (from 731 ± 897 mm3 at baseline to
539 ± 1017 mm3; P = 0.5), but there was a correlation
of 0.91 between baseline glandular volume and glandular
volume following treatment with cinacalcet. There was no
statistically significant association between serum iPTH
and parathyroid gland size at baseline or at the end of the
study. A summary of the change in sonographic patterns
before and after treatment is reported in Table 4.
Fifteen glands had a baseline volume <500 mm3. The
mean volume ± SD of these glands changed significantly
during the course of the study (from 233 ± 115 mm3 at
baseline to 102 ± 132 mm3; P = 0.007), with a mean de-
crease in volume of 68% (Figures 3A and 4 and Table 4).
At the end of the follow-up period, five glands had be-
come indistinguishable from the thyroid parenchyma, nine
glands had diminished in volume and one gland was en-
larged, due to the appearance of an extended anechoic area
within the nodule. Moreover, eight glands acquired a hy-
perechoic pattern, six became hypovascularized and seven
became avascularized. Anechoic areas of cystic degenera-
tion appeared in five glands, which had a baseline volume
>350 mm3.
Thirteen glands had a baseline volume ≥500 mm3. The
mean volume ± SD of these glands did not change statis-
tically significantly during the course of the study (from
1036 ± 1062 mm3 at baseline to 837 ± 1290 mm3; P =
0.3) (Figure 3B and Table 4), with a mean reduction per-
centage of volume of 54% (Figure 4). By the end of the
follow-up period, 11 glands had reduced in volume, 1 gland
had no change in volume and 1 gland was enlarged, due to
the appearance of extended anechoic areas of cystic degen-
eration. Figure 5 shows 1 of the 11 glands that had reduced
in volume: at baseline, 12 months following treatment with
cinacalcet and at the end of the follow-up period. Of the
13 glands analysed, 8 acquired a hyperechoic pattern and
8 glands showed extended anechoic areas of cystic degen-
eration. During the course of the study, six glands became
hypovascularized and seven became avascularized. A sum-
mary of the vascular pattern changes is outlined in Figure 6.
Effect of interruption of cinacalcet treatment
After a 2-week suspension, a rebound of serum iPTH levels
occurred in all patients, even in those who had shownmajor
involutive phenomena and lower values of iPTH at the end
of the follow-up. The reintroduction of cinacalcet led to
another reduction in serum iPTH levels in all patients. The
results of this experiment are given in Figure 7.
Discussion
Phase II and III studies have shown that cinacalcet suc-
cessfully lowers serum iPTH in MHD patients with sHPT,
simultaneously controlling parameters associated with the
Ca–P balance [21,22]. Long-term studies have given similar
results [30]. An experimental study showed that stabiliza-
tion of mineral metabolism parameters was accompanied
by a decrease in parathyroid hyperplasia in uraemic rat
models treated with cinacalcet, with no evidence of in-
creased apoptosis [31]. To date, there has been a lack of
experimental models or studies focused on the effect of
cinacalcet on nodular hyperplasia. Furthermore, no data
have been published regarding the effect of cinacalcet on
potential morphological variations in hyperplastic parathy-
roid glands in CKD patients with severe sHPT. Clinical
evaluation of sHPT is usually carried out by the assessment
of biochemical parameters rather than via morphological
measurements. The aim of this observational study was to
investigate the effects of long-term therapy with cinacalcet,
in association with conventional therapy, on the morphol-
ogy of hyperplastic parathyroid glands.
We show here that cinacalcet had a more rapid effect on
the biochemical profile of sHPT than on the morphology of
parathyroid glands. Changes in volume, vascularization and
sonographic pattern were observed after 12–18 months of
therapy. After this time, we observed a progressive change
in the structural pattern of hyperplastic glands. Glands with
a baseline volume ≥500 mm3 had a tendency to show
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Fig. 3. (A) Volume changes in glands with baseline volume <500 mm3 following treatment with cinacalcet. Fifteen glands had a baseline volume
<500 mm3. The mean volume ± SD changed from f ± 115 mm3 at baseline to 102 ± 132 mm3 at the end of follow-up (P = 0.007). (B) Volume
changes in glands with baseline volume ≥500 mm3 following treatment with cinacalcet. Thirteen glands had a baseline volume ≥500 mm3. The mean
volume ± SD changed from 1036 ± 1062 mm3 at baseline to 837 ± 1290 mm3 at the end of follow-up (P = 0.3).
Fig. 4. Percentage of volume reduction in glands with a baseline volume
<500 and ≥500 mm3, means and SDs.
involutive phenomena, such as anechoic areas of cystic de-
generation. This was associated with a decrease in glandu-
lar volume in all but one case, where gland size increased.
In glands with a baseline volume <500 mm3, there were
more significant changes in volume. There was a tendency
for the structural pattern of these glands to change from
hypoechoic (suggesting that they were hyperplastic with a
rich cellularity) to hyperechoic (suggesting that they were
quiescent with an increased number of adipose cells). In the
most significant cases, glands became very small and, like
normal parathyroid glands, were indistinguishable from the
thyroid parenchyma.
We have noted a relationship between major involutive
phenomena and a major reduction in iPTH and Ca serum
levels, suggesting that a lower dose of cinacalcet may have
been used. Interestingly, independent of baseline volume,
glands that became hypovascularized following cinacal-
cet treatment inversely reproduced the progression of the
parathyroid gland to hyperplasia (i.e. from a hypovascular-
ized to a hypervascularized pattern).
Critical analysis of these data suggests that stabilization
of the biochemical profile of sHPT, as well as the invo-
lutive phenomena in the glands, was observed only after
the introduction of cinacalcet in the therapeutical schema.
These observations suggest that cinacalcet is able to modu-
late the biological response of parathyroid cells in synergy
with vitamin D and phosphate binders. So, the degenerative
effects that are observed during long-term treatment have
to be considered as a result of a combined pharmacological
effect.
Cystic degeneration and hypovascularization were evi-
dent in glands with diffuse and nodular hyperplasia. Phys-
iopathological mechanisms responsible for glandular de-
generation are unknown and should be the objective of
further studies. At the moment, findings do not support or
exclude the possibility that glandular degeneration is due to
enhanced apoptosis [32] as well as to an indirect effect of
cinacalcet on the vessel tree [33]. Nevertheless, it should be
noted that a recent study has reported a pro-apoptotic effect
of cinacalcet in glands with nodular hyperplasia excised in
patients not previously treated with phosphate binders or
vitamin D [34].
To determine whether cinacalcet could be considered the
trigger of the functional response of hyperplastic glands,
cinacalcet therapy was interrupted temporarily in a small
number of patients. After 2 weeks of suspension, serum
iPTH levels increased in all patients, even in those who had
the major involutive phenomena. Interestingly, the increase
in serum iPTH values was smaller as compared with ini-
tial PTH levels (mean values close to 1200 pg/ml). One
explanation might be that PTH secretion was lower after
long-term cinacalcet therapy due to a reduction in the num-
ber of functional parathyroid cells (mass reduction). These
data, although not definitive, are interesting: they demon-
strate the efficacy of the drug on biochemical and func-
tional profiles, but they are contradictory because they do
not demonstrate a clear association between involutive phe-
nomena and a reduction in function of the glands. Possible
explanations for this could be linked to the persistence of
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Fig. 5. Longitudinal scans of the right thyroid lobe before and after cinacalcet treatment. A parathyroid gland with a nodular, hypoechoic pattern is
shown behind the thyroid lobe. (a) Baseline image acquired with high-resolution colour Doppler (CD) showing a vascular hilumwith ray-like centrifugal
vessels. Baseline iPTH was 1623 pg/ml and gland volume was 1337 mm3. (b) The same gland after 12 months, showing a reduced volume and a
hypovascular pattern. (c) CD sampling at low pulse repetition frequency (800 kHz) at the end of follow-up, showing a significant volume reduction
(1337 mm3 versus 608 mm3), the complete absence of endonodular perfusion and the appearance of an anechoic area of cystic degeneration. Patient
intact parathyroid hormone was 148 pg/ml.
Fig. 6. Vascular pattern of glands at baseline and at the end of follow-up.
glandular cellular masses that are no longer inhibited after
the suspension of the drug or to the possibility that the ap-
parent cellular necrosis is not sufficiently complete to with-
stand interruption of the drug. Furthermore, the response
seen in iPTH after discontinuation and reintroduction of
cinacalcet suggests that the remnant parathyroid tissue re-
sponded to stimulation of the CaR. These findings confirm
the evidence from pre-clinical studies that show that cal-
cimimetics inhibit parathyroid hyperplasia [35] in subto-
tally nephrectomized rats [31]. However, it should be noted
that cellular cultures in vitro [36] and the post-5/6 nephrec-
tomy rat model of secondary HPT are not a true reflection
of the progression of nodular hyperplasia in humans [31].
The main limitations of this study were the small num-
ber of patients and that data for the control patients were
collected retrospectively. In addition, some analyses were
Fig. 7. Variations in serum intact parathyroid hormone (iPTH) levels
following the suspension and the reintroduction of cinacalcet.
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based on the number of glands, but the changes in gland
volume within a patient are unlikely to be independent, and
this has not been accounted for in the statistical analyses.
In summary, the practical consequences of these prelim-
inary data are the need for a combination of cinacalcet with
conventional therapy and also the monitoring of the glan-
dular response with morphological parameters. Finally, the
reductions in glandular volume and vascularization, partic-
ularly in smaller glands, provide a strong argument for the
early use of cinacalcet (and at lower doses) in combina-
tion with standard therapy. Early ‘pharmacological PTX’,
using cinacalcet in combination with conventional therapy,
could reduce the number of patients who eventually require
a surgical PTX.
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